Dexpanthenol
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Dexpanthenol: From Topical Skin-Care Use to Anorectal Stricture
One-Sentence Summary
Dexpanthenol is a topical skin-care ingredient. The US records list it in eyelash serums and a baby ointment, with no formal approved indication text. The TxGNN model predicts it may be effective for anorectal stricture (score 99.72%), but 0 clinical trials and 0 publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the license records (products are two eyelash serums and a baby ointment) |
| Predicted New Indication | Anorectal stricture |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the source record. Dexpanthenol is converted in the body to pantothenic acid (vitamin B5), a precursor of coenzyme A. It supports epithelial proliferation and mucosal healing, which is why it is used in skin and mucosal care products.
The link to the predicted indication is weak. Anorectal stricture is a fibrotic, structural narrowing. Topical healing support is not known to reverse it, so the connection is speculative. The high score most likely reflects proximity in the knowledge graph rather than a demonstrated pharmacological effect. No clinical or literature evidence was supplied for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M018 | Eyelash Serum (FlexiGo Inc) | Liquid | Not stated |
| Not provided | ReOrganic Eyelash Growth Boosting Serum (LAON COMMERCE co ltd) | Liquid | Not stated |
| Not provided | BABYSONS (Laboratorios Quimica Son’s, S.A. de C.V) | Ointment | Not stated |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials or publications for anorectal stricture. The plausible mechanism (mucosal healing support) does not address a fibrotic structural condition.
To proceed, the following is needed:
- A targeted literature and trial search on dexpanthenol for anorectal conditions, including post-operative or radiation-related mucosal injury.
- Package insert warnings and contraindications, which are needed before any safety screening.
- Mechanism-of-action data from DrugBank.
- Route and formulation compatibility. The current products are eyelash serums and a topical ointment, and no route is defined for anorectal use.
- Other predictions for this drug are better candidates for follow-up:
- Punctate epithelial keratoconjunctivitis (score 99.34%) has the most coherent mechanism, through corneal epithelial healing. Ophthalmic dexpanthenol for corneal epithelial defects and dry eye is the logical next search.
- Exanthem (score 99.60%) is the only prediction with registered trials, but they are indirect (post-procedure or dermatitis-type skin reactions). The strongest is a completed Phase 3 randomized trial of Bepanthen cream (NCT01136005, n=160), which addresses a dermatitis-type reaction rather than exanthem.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.